Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
